The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
we also get into why hdl cholesterol is a far less relevant metric at least why we believe that to be the case we then pivot a little bit and talk about risk assessment basically how do you understand these metrics how do you use these metrics this is a lot of the clinician type stuff here around apob and triglyceride rich lipoproteins
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.